Evidence used
- No CISA KEV confirmation is currently recorded.
- EPSS is 0.95% for the current model date.
BlackTreeCVE IntelligenceUnknown · Unknown
High technical severity; prioritise exposed affected systems while verifying vendor guidance.
High technical severity; prioritise exposed affected systems while verifying vendor guidance.
Fix not verifiedIn Code42 for Enterprise through 6.8.4, an administrator without web restore permission but with the ability to manage users in an organization can impersonate a user with web restore permission. When requesting the token to do a web restore, an administrator with permission to manage a user could request the token of that user. If the administrator was not authorized to perform web restores but the user was authorized to perform web restores, this would allow the administrator to impersonate the user with greater permissions. In order to exploit this vulnerability, the user would have to be an administrator with access to manage an organization with a user with greater permissions than themselves.
In Code42 for Enterprise through 6.8.4, an administrator without web restore permission but with the ability to manage users in an organization can impersonate a user with web restore permission. When requesting the token to do a web restore, an administrator with permission to manage a user could request the token of that user. If the administrator was not authorized to perform web restores but the user was authorized to perform web restores, this would allow the administrator to impersonate the user with greater permissions. In order to exploit this vulnerability, the user would have to be an administrator with access to manage an organization with a user with greater permissions than themselves.
The product does not properly assign, modify, track, or check privileges for an actor, creating an unintended sphere of control for that actor.
An attacker operating through a network path may attempt exploitation with low privileges. If successful, the issue may cause the confidentiality, integrity or availability impact described by the vendor.
In Code42 for Enterprise through 6.8.4, an administrator without web restore permission but with the ability to manage users in an organization can impersonate a user with web restore permission. When requesting the token to do a web restore, an administrator with permission to manage a user could request the token of that user. If the administrator was not authorized to perform web restores but the user was authorized to perform web restores, this would allow the administrator to impersonate the user with greater permissions. In order to exploit this vulnerability, the user would have to be an administrator with access to manage an organization with a user with greater permissions than themselves.
The product does not properly assign, modify, track, or check privileges for an actor, creating an unintended sphere of control for that actor.
An attacker operating through a network path may attempt exploitation with low privileges. If successful, the issue may cause the confidentiality, integrity or availability impact described by the vendor.
CVSS severity, EPSS forecast probability, public exploit material and CISA-confirmed exploitation are separate signals.
No CISA KEV match was present at the last successful refresh. This means no confirmation from that source, not proof of no exploitation.
No exploit-tagged reference or CISA SSVC proof-of-concept state is currently recorded. Research may still exist outside the structured feeds.
CWE-269: Improper Privilege Management. The product does not properly assign, modify, track, or check privileges for an actor, creating an unintended sphere of control for that actor.
CVSS:3.0/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:HCommon Vulnerability Scoring System 3.0: the compact vector below is decoded into plain language.
Operational remediation based on structured source evidence.
Published 19 Jul 2019 · Last source change 4 Aug 2024, 22:55 UTC · CWE-269 · Improper Privilege Management
Missing structured fields: affected product. Missing data is not evidence of low risk; review the primary advisory.